ALX Oncology cancer drug claims two FDA fast-track reviewsFresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations Share XALX Oncology cancer drug claims two FDA fast-track reviewshttps://pharmaphorum.com/news/alx-oncology-cancer-drug-claims-two-fda-fast-track-reviews/
